Charles River Laboratories Intl. Inc vs Palo Alto Networks Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $301.79 (market cap $14.23B), while Palo Alto Networks Inc trades at $418.78 (market cap $331.76B). The key difference: Palo Alto Networks Inc is far larger — about 23.3× Charles River Laboratories Intl. Inc's market cap, and Palo Alto Networks Inc is more actively traded (3,886,927 versus 1,176,885). Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Palo Alto Networks Inc for 82 Days on average.
| CRL | PANW | |
|---|---|---|
Market Cap | $14.23B | $331.76B |
Volume | 1,176,885 | 3,886,927 |
Sector | Health | Technology |
52-Week High | $310.77 | $419.91 |
52-Week Low | $149.93 | $141.67 |
Typical Hold Time | 33 Days | 82 Days |
Enterprise Value | $17.06B | $331.19B |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $298, down 0.77% on the day, with strong analyst support showing 73% buy ratings and a $305.50 consensus price target. The stock maintains a bullish technical outlook with support at $292 and resistance at $301, while recent earnings have consistently beaten expectations despite negative net income margins. The company's 2026 Investor Day highlighted a strategic vision targeting 5-7% organic growth and $300 million in savings by 2030.
CRL presents a compelling growth story with solid operational cash flow and strategic initiatives, though investors face risks from negative profitability metrics and elevated valuation multiples. The stock's current position near analyst targets suggests limited upside without improved earnings execution, while ongoing margin pressures and debt levels require careful monitoring amid the company's transformation efforts.
Palo Alto Networks trades at $398.50, down 1.7% today but remains near recent highs. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Revenue growth continues at $9.22 billion for 2025, though profitability metrics show mixed results with high gross margins but modest net income margins. The company's AI security initiatives are driving positive media coverage and investor optimism.
Outlook remains positive given strong analyst consensus (72% buy ratings) and AI-driven cybersecurity demand, but premium valuations and execution risks warrant caution. The stock trades near its consensus price target of $398.70, suggesting limited near-term upside without significant earnings acceleration or multiple expansion.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Palo Alto Networks is a pure-play cybersecurity vendor that sells security appliances, subscriptions, and support into enterprises, government entities, and service providers. The company's product portfolio includes firewall appliances, virtual firewalls, endpoint protection, cloud security, and cybersecurity analytics. The Santa Clara, California, firm was established in 2005 and sells its products worldwide.
Read more on PANW →